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Breast cancer and osteoporotic fractures aﬀ  ect one in 
eight and one in three women, respectively, during life-
time, ranking these two diseases high on the women’s 
health agenda. In recent years, screening programs have 
been established and eﬃ   cient therapies for the treatment 
of both diseases have become available. Hormone 
replace  ment therapy is eﬀ   ective against bone loss in 
postmenopausal osteoporosis, but is associated with 
increased incidence of breast cancer. By contrast, some 
therapies against osteoporosis may protect against breast 
cancer, including raloxifene [1] and bisphosphonates [2,3].
Th  ere may be even closer links between these two 
disorders at the molecular level, involving the receptor 
activator of nuclear factor-κB ligand (RANKL). Its major 
role in human physiology is to control the diﬀ  erentiation 
and activation of osteoclasts, the bone cells specialized to 
break down bone [4]. Osteoclasts initiate a sequence of 
events whereby bone of poor quality is removed and 
replaced by new bone. Th  is remodeling process con-
stantly repairs the skeleton. Th   e delicate balance between 
resorption and formation of bone can be severely 
impaired by declining sex steroid hormones, as in meno-
pause, or during adjuvant therapy for breast or prostate 
cancer [5]. At the cellular level, up-regulation of RANKL 
promotes osteoclast diﬀ  erentiation and activity, induces 
excessive bone resorption, and leads to osteoporotic 
fractures. Th   is common theme applies to several impor-
tant bone loss disorders, including postmenopausal 
osteo  porosis and osteoporosis associated with aromatase 
inhibitor and androgen-ablative therapy, osteolytic meta-
stases, myeloma bone disease, and giant cell tumors of 
the bone [5]. Based on its fundamental role in skeletal 
homeostasis, RANKL has become a therapeutic target in 
the treatment of bone disorders, and a monoclonal anti-
body against RANKL, denosumab, has been approved for 
the treatment of postmenopausal osteoporosis [6].
Since its discovery, the RANKL/RANK pathway has 
been implicated in the modulation of several extra-
skeletal processes, including development of the immune 
system, vascular biology, skin homeostasis, central control 
of body temperature, and breast development. For 
instance, mice that were deﬁ  cient of RANK, the receptor 
of RANKL, did not develop a lactating mammary gland, 
and their oﬀ  spring died as a result of starvation [7]. Th  e 
dual role of RANKL/RANK in releasing calcium and 
other minerals from bone and permitting lactation 
indicates an evolutionary key role in calcium transfer 
across generations. Whether the RANKL/RANK path-
way also controls epithelial cell growth in breast cancer 
has long remained unclear.
Recently, two groups have demonstrated that RANKL 
may be crucial for breast cancer development. Both 
groups employed a carcinogen-induced murine mammary 
tumor model supplemented with progesterone, which 
leads to the development of hormone receptor-positive 
mammary tumors [8,9]. Upon repeated administration of 
the carcinogen DMBA (7,12-dimethylbenz[α]anthra  cene), 
along with the progestin medroxy  progesterone acetate, 
mice developed mammary tumors that were associated 
with increased RANKL expression in the progesterone 
receptor-positive epithelial compo  nent [8,9] and 
expansion of the CD24-positive/highly CD49-positive 
cell fraction, a breast cancer stem cell population [8]. 
RANK-transgenic mice that overexpress the receptor of 
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Receptor activator of nuclear factor-κB ligand (RANKL) 
plays a pivotal role in regulating bone homeostasis. 
Osteoporosis and malignant bone disease secondary 
to breast cancer are characterized by enhanced 
RANKL production and increased bone turnover. Thus, 
denosumab, a monoclonal antibody to RANKL, has 
been developed and is now approved for various bone 
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also promote the development and osseous migration 
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after multiparity or medroxyprogesterone acetate 
treatment [9], whereas interruption of RANKL/RANK 
signaling attenuated progestin-driven breast cancer. Th  e 
latter was achieved by two diﬀ  erent approaches, the use 
of RANKΔmam mice, in which RANKL has no mammary 
receptor for its action [8], or application of RANK-Fc 
protein, which neutralises the eﬀ  ects of RANKL [9].
Taken together, the two studies clearly show that 
RANKL is involved in the development of carcinogen-
induced mammary tumorigenesis in mice in the setting 
of progesterone treatment, and provided proof-of-
concept that blockade of RANKL may attenuate this 
process. Th  ese ﬁ   ndings complement an earlier study 
from Josef Penninger’s group where RANKL enhanced 
breast cancer cell migration into bone and spurred the 
development of bone metastases [10]. However, these 
ﬁ   ndings are applicable only to the hormone receptor-
positive variant of breast cancer, and not to hormone 
receptor-negative breast cancer, the more aggressive 
subtype. Th  e ﬁ   rst translational hurdle to be taken 
includes a careful characterization of the RANKL/RANK 
signaling pathway in the development of human breast 
cancer. If this is conﬁ  rmed, one could envision that the 
RANK status may be determined from human breast 
cancer specimens, already a routine procedure for the 
estrogen receptor, the progesterone receptor, and HER2, 
the receptor for epidermal growth factor. Obviously, one 
could hypothesize that RANKL blockade with 
denosumab [6] may be used to prevent breast cancer. A 
long-term follow-up of the breast cancer incidence in 
women who had received denosumab for 3 years in the 
FREEDOM trial [6] may corroborate this hypothesis, and 
recent results from a study comparing denosumab with 
zoledronic acid in women with advanced breast cancer 
indicate superiority of denosumab in preventing skeletal-
related events [11]. A prospective study is currently 
assessing the eﬀ  ects of denosumab in women with early 
breast cancer (NCT01077154). Th  is will reveal whether 
this promising news from basic research can live up to 
the great expectations.
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